Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2024.111183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Fan Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Inn…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Carcinoma, Hepatocellular, Liver Neoplasms, Glycolysis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, with Hepatitis B virus (HBV) infection being the leading cause. This study aims to investigate the role of HBV in HCC pathogenesis involving glucose metabolism. Long non-coding RNA (lncRNA) OIP5-AS1 was significantly downregulated in HBV-positive HCC patients, and its low expression indicated a poor prognosis. This lncRNA was primarily localized in the cytoplasm, acting as a tumor suppressor. HBV protein X (HBx) repressed OIP5-AS1 expression by inhibiting a ligand-activated transcriptional factor peroxisome proliferator-activated receptor α (PPARα). Furthermore, mechanistic studies revealed that OIP5-AS1 inhibited tumor growth by suppressing Hexokinase domain component 1 (HKDC1)-mediated glycolysis. The expression of HKDC1 could be enhanced by transcriptional factor sterol regulatory element-binding protein 1 (SREBP1). OIP5-AS1 facilitated the ubiquitination and degradation of SREBP1 to suppress HKDC1 transcription, which inhibited glycolysis. The results suggest that lncRNA OIP5-AS1 plays an anti-oncogenic role in HBV-positive HCC via the HBx/OIP5-AS1/HKDC1 axis, providing a promising diagnostic marker and therapeutic target for HBV-positive HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The…
- Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, PR China.
- Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.
- Clinical Laboratory Department, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, Zhejiang 315700, PR China. Electronic address: linjj1122@163.com.
Zitieren
APA
Shi, F., Jiang, J., Wang, B., Hong, L., Zhang, Y., Meng, Y., Zhang, X., Gong, L., Lin, J., & Diao, H. (2024). Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111183
Vancouver
Shi F, Jiang J, Wang B, Hong L, Zhang Y, Meng Y, et al. Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111183
BibTeX
@article{Shi2024,
author = {Shi, Fan and Jiang, Jingjing and Wang, Baohua and Hong, Liang and Zhang, Yongting and Meng, Yuting and Zhang, Xujun and Gong, Lan and Lin, Jianjun and Diao, Hongyan},
title = {Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2024.111183}
}
EUVIMED